Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.

Masaki KatoMasako ShiosakaiKazuo KuwaharaKatsuhiro IbaYuki ShimadaMizuki SaitoYuki IsogaiDaisuke SekineKazuo AokiNobuyuki KogaTeruhiko Higuchi

Published in: Psychiatry and clinical neurosciences (2023)

Brexpiprazole 1 mg daily was an appropriate starting dose and both 1 mg and 2 mg daily were effective and well tolerated as adjunctive therapy for Japanese MDD patients not adequately responsive to ADT. This article is protected by copyright. All rights reserved.

Keyphrases

major depressive disorder
bipolar disorder
double blind
placebo controlled
end stage renal disease
physical activity
clinical trial
chronic kidney disease
newly diagnosed
phase iii
open label
randomized controlled trial
phase ii
peritoneal dialysis